Analysts: Facebook Will Benefit From Strong Ad Sales and 3 More Research Notes to Look Over

Facebook (NASDAQ:FB): Cantor sees Facebook’s valuation as compelling, and expects Facebook to benefit from strong mobile ad sales and growing overall user engagement in Q2, along with lucrative video ads later this summer. The firm keeps a $35 price target and reiterates a Buy rating on the shares.


Rogers Communications (NYSE:RCI): BMO Capital has lowered its rating on Rogers to Market Perform from Outperform, due to Verizon’s (NYSE:VZ) potential entry into the Canadian market. The firm also lowered its price target to $45 from $54.


United Therapeutics (NASDAQ:UTHR): Leerink doesn’t see the Markman ruling in United Therapeutics’ Remodulin patent litigation case with Sandoz as surprising, and notes that only two of three Orange Book listed patents for Remodulin were subject of claims construction. Leerink continues to see significant generic risk to the Remodulin franchise and reiterates a Market Perform rating on the stock.


Amarin (NASDAQ:AMRN): Wainwright has initiated coverage of Wainwright with a Neutral rating and a $6 price target, as it sees a low probability of Amarin announcing a commercial partnership or acquisition.


Don’t Miss: Facebook App Coming for Windows 8!